In recent years, drugs acting on the GLP-1 system  have become central to the treatment of obesity. Originally developed for diabetes, these medications (e.g., Wegovy and Mounjaro) have demonstrated remarkable efficacy in controlling appetite and promoting weight loss. Today, however, research is suggesting something even more intriguing: these drugs might also play a role in reducing the risk of addiction. A recent article published in Nature  highlights findings from a larg

Alzheimer's disease has long been associated with amyloid plaques and tau tangles. However, recent metabolic research has shifted some focus toward insulin signaling dysfunction in the brain. This emerging perspective is crucial for understanding the complexities of Alzheimer’s. The concept of “type 3 diabetes” gained traction following the seminal 2008 paper by de la Monte & Wands . They described impaired insulin and IGF signaling in Alzheimer’s brains. Their findings propo

The supplement industry is evolving rapidly, driven by new scientific discoveries and changing consumer demands. One of the most promising developments is the rise of GLP-1 drugs, originally designed for managing diabetes and obesity. These drugs are now gaining attention as potential companions to traditional supplements, offering new ways to support health and wellness. This post explores how GLP-1 drugs could reshape the supplement landscape and what that means for consume